We would again like to thank all participants of the 2020 virtual Extramural meeting for their attendance and for all the questions and comments we received. Please find the report of the meeting in our meetings section.
The dates for the various EPT exercises for 2021 have been sent to the participating laboratories and have been published on our website. In case one of these dates interferes with some special events, please inform us as soon as possible.
Sample shipments
Shipping date
Typing Dispatch (n)
Deadline Typing/XM Report
Crossmatch Dispatch*
Screening Dispatch*
Deadline screening Report
23-02-2021
3
09-03-2021
EPT-XM-A, B, C
EPT-Scr-A-L
06-07-2021
13-04-2021
3
27-04-2021
EPT-XM-D, E, F
x
x
15-06-2021
3
29-06-2021
EPT-XM-G, H, I
x
x
21-09-2021
3
05-10-2021
EPT-XM-J, K, L
x
x
*Please note that for screening and cross matching different sera are shipped
The results of the Eurotransplant EPT on typing and crossmatching, samples 2020 19/20/21 and 2020 22/23/24 are published on the EPT website (www.etrl.org).
In case of inconsistencies, please inform us as soon as possible.
We would like to thank all participants of the 2020 virtual Extramural meeting for their attendance and for all the questions and comments we received. Please find all presentations of the meeting in our meetings section.
The 2020 autumn Newsletter has been published and contains information on the progress of the transition to the virtual crossmatch in Eurotransplant, some news on data extracts, the extra EPT shipment, and on a new form for AM patient updates.
Due to the Corona pandemic the Extramural meeting that was planned on the 13th of March 2020 in Mechelen, Belgium was cancelled. Since a physical meeting will not be possible in the foreseen future, the ETRL will host a virtual Extramural meeting on Wednesday the 27th of November from 9:30 till 13:00. The preliminary program is as follows:
Overview EPT results 2019 Yvonne Zoet (ETRL)
Patient based cases 2019 (a summary of results is published on the EPT website) Yvonne Zoet (ETRL)
News from the TTAC Sebastiaan Heidt (ETRL)
The road towards virtual crossmatching Sebastiaan Heidt (ETRL)
HLA epitopes: from theory to practice Cynthia Kramer(LUMC)
The 2020 spring Newsletter has been published and contains information on the introduction of the vPRA, and an update on the EPT scheme changes due to Corona.
Because of the Corona pandemic we were forced to postpone the March shipment and the May shipment will also be postponed. Since governmental restrictions are now gradually scaled down, we have decided to make a new shipment schedule for the EPT on the 2020 typing and crossmatching, as well as for the patient- based cases. Additionally, we decided to temporarily prolong the deadlines from 2 to 3 weeks.
Please note that at the moment there is still a possibility that we are not able or allowed to ship on the dates announced. Whenever necessary we will reschedule again and keep you updated. There will be an extra shipment in January for the laboratories that do not yet meet the criteria or were unable to receive any of the planned shipments. The date of this extra shipment will be announced at a later time.
Shipping date
Typing Dispatch (n)
Deadline typing and xm report
Screening Dispatch (n)
Crossmatch Dispatch*
Deadline screening report
04-02-2020
3
18-02-2020
EPT-Scr-A-L (12 sera)
EPT-XM- A, B, C
07-07-2020
16-06-2020
3
07-07-2020
x
EPT-XM- D, E, F
x
08-09-2020
3
29-09-2020
x
EPT-XM- G, H, I
x
03-11-2020
3
24-11-2020
x
EPT-XM- J, K, L
x
*For screening and crossmatching different sera are shipped
Patient-based cases EPT
Information/form sent
Deadline results
04-02-2020
18-02-2020
16-06-2020
07-07-2020
03-11-2020
24-11-2020
Please let us know before the 21st of May 2020 if the proposed shipment dates and/or deadlines will be problematic for you. Also, when you have any other questions, please do not hesitate to contact us.
The paper entitled “Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR has been accepted for publication by the American Journal of Transplantation. The manuscript describes how we have developed human recombinant monoclonal antibodies (mAbs) against HLA-DR, as well as the analysis of the amino acids/eplets recognised by these mAbs.
This site uses functional cookies and external scripts to improve your experience. Which cookies and scripts are used and how they impact your visit is specified on the left. You may change your settings at any time. Your choices will not impact your visit.
NOTE: These settings will only apply to the browser and device you are currently using.